Latest news and press releases about AbbVie Inc. (ABBV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active...
Price
| Price | $265.76 |
| Market Cap | $469.5B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 74.05 |
| Price / Book | -78.42 |
| EV / EBITDA | 24.89 |
| Dividend Yield | 2.60% |
Profitability
| Return on Equity | -136.50% |
| Return on Invested Capital | 13.46% |
| Return on Assets | 4.67% |
| Gross Margin | 71.48% |
| Operating Margin | 29.32% |
| Net Margin | 9.81% |
Related companies: AMGN · AZN · GILD · JNJ · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of ABBV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks